Fisher & Paykel Healthcare raises guidance
By HME News Staff
Updated 9:38 AM CST, Mon February 23, 2026
.jpg)
AUCKLAND, New Zealand – Fisher & Paykel Healthcare now expects full-year operating revenue to be about $2.3 billion, and net profit after tax to be in the range of about $450 million to $470 million. Previously, the company said it expected operating revenue in the range of about $2.17 billion to $2.27 billion and full-year net profit after tax of about $410 million to $460 million. “While relative seasonal respiratory hospitalizations in the Northern Hemisphere winter may continue to impact the second half result, our performance to date suggests pleasing progress in our efforts to change clinical practice,” said Lewis Gradon, managing director and CEO. “Continuous improvement activities and other efficiency gains are also contributing to improvements in our gross margin and operating margin.” F&P Healthcare says the updated guidance does not incorporate any potential refund of U.S. tariffs paid to date during the 2026 financial year, following the U.S. Supreme Court’s decision to invalidate tariffs imposed by the administration under the International Emergency Economic Powers Act. The company says it continues to work through the complexities associated with the court ruling, refund processes and application of free trade agreements and the Nairobi Protocol to its products, and will provide an update on tariff impacts with its full-year results at the end of May.
Comments